Study guide

8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs

Key Takeaways Explain This Topic AI

The adult junctional nicotinic acetylcholine receptor ( n A C h R nAChR n A C h R ) is a pentamer of ( α 1 ) 2 β 1 δ ϵ (\alpha_1)_2 \beta_1 \delta \epsilon ( α 1 ​ ) 2 ​ β 1 ​ δϵ ; denervation, burn injury, or prolonged immobility induces upregulation of immature embryonic ( α 1 ) 2 β 1 δ γ (\alpha_1)_2 \beta_1 \delta \gamma ( α 1 ​ ) 2 ​ β 1 ​ δ γ and homomeric α 7 \alpha_7 α 7 ​ extrajunctional receptors that remain open longer and trigger lethal hyperkalemic responses to suxamethonium.

Suxamethonium produces a depolarizing Phase I block characterized by initial muscle fasciculations, lack of fade on Train-of-Four stimulation, and absence of post-tetanic potentiation; prolonged exposure or high doses convert it into a Phase II desensitization block showing fade and post-tetanic facilitation.

Butyrylcholinesterase (pseudocholinesterase) hydrolyzes suxamethonium; individuals homozygous for the atypical gene ( E 1 a E 1 a E_1^a E_1^a E 1 a ​ E 1 a ​ ) have a dibucaine number of approximately 20% and experience profound, flaccid neuromuscular apnea lasting 4 to 8 hours.

Atracurium and cisatracurium undergo organ-independent Hofmann elimination; cisatracurium is 3 to 4 times more potent, produces negligible amounts of the epileptogenic metabolite laudanosine, and causes zero histamine release.

Rocuronium achieves rapid intubation onset within 60 to 90 seconds at a dose of 1.2 mg/kg due to its low potency generating a high molar biophase diffusion gradient; it is cleared primarily by hepatic uptake and biliary excretion without active metabolites.

Last updated: October 2026

8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs

Neuromuscular blocking drugs (NMBDs) interrupt neurotransmission at the skeletal motor endplate. They are classified into depolarizing agents (suxamethonium) and non-depolarizing agents (benzylisoquinoliniums and aminosteroids). Mastery of their receptor interactions, degradation kinetics, active metabolites, and clinical toxicity profiles is fundamental to modern anaesthesia.

1. Neuromuscular Junction Physiology and Receptor Architecture

Skeletal muscle contraction requires sequential electrical, chemical, and electrochemical signaling across the neuromuscular junction (NMJ). [ PRESYNAPTIC MOTOR NERVE TERMINAL ]

  • |
  • Action Potential Depolarization
  • |
  • Voltage-gated P/Q-type $Ca^{2+}$ Channels Open
  • |
  • $Ca^{2+}$ Influx Triggers SNARE Fusion
  • |
  • ACh Released into Synaptic Cleft (50 nm)
  • |
  • +-----------------------------+-----------------------------+
  • | |
  • v v
  • [ POSTSYNAPTIC MEMBRANE ] [ SYNAPTIC CLEFT ]
  • Two ACh molecules bind two $\alpha_1$ subunits Acetylcholinesterase
  • Heteropentamer: $(\alpha_1)_2 \beta_1 \delta \epsilon$ Hydrolyzes ACh in <1 ms
  • Central ionophore opens $\rightarrow$ $Na^+/Ca^{2+}$ enter into choline & acetate
  • Endplate Potential (EPP) propagates along sarcolemma
  • The Postsynaptic Nicotinic Acetylcholine Receptor ( n A C h R nAChR n A C h R )

The postsynaptic n A C h R nAChR n A C h R is a member of the Cys-loop ligand-gated ion channel superfamily. It consists of five glycoprotein subunits arranged circumferentially around a central water-filled ion conducting pore:

Adult Junctional Receptor: Heteropentamer composed of two α 1 \alpha_1 α 1 ​ , one β 1 \beta_1 β 1 ​ , one δ \delta δ , and one ϵ \epsilon ϵ subunit [ ( α 1 ) 2 β 1 δ ϵ (\alpha_1)_2 \beta_1 \delta \epsilon ( α 1 ​ ) 2 ​ β 1 ​ δϵ ]. Channel opening requires the simultaneous binding of two acetylcholine molecules to the two α 1 \alpha_1 α 1 ​ subunits (at the α − δ \alpha-\delta α − δ and α − ϵ \alpha-\epsilon α − ϵ interfaces). This induces a conformational rotation that opens the channel for ~1 millisecond, conducting an inward flow of N a + Na^+ N a + and C a 2 + Ca^{2+} C a 2 + and an outward flow of K + K^+ K + .

Fetal / Immature Extrajunctional Receptors: Synthesized in developing fetal muscle and re-expressed following motor denervation, thermal burn injury, or prolonged immobilization. They consist of an embryonic heteropentamer where the ϵ \epsilon ϵ subunit is replaced by a γ \gamma γ subunit [ ( α 1 ) 2 β 1 δ γ (\alpha_1)_2 \beta_1 \delta \gamma ( α 1 ​ ) 2 ​ β 1 ​ δ γ ] or a homopentamer of α 7 \alpha_7 α 7 ​ subunits .

Characteristics of Extrajunctional Receptors

Distribution: Spread across the entire muscle sarcolemma beyond the confines of the motor endplate.

Conductance and Kinetics: Extrajunctional receptors have lower single-channel conductance but a 2- to 10-fold longer mean channel open time than mature adult receptors.

Pharmacological Sensitivity: Exquisitely sensitive to depolarizing drugs (suxamethonium) and relatively resistant to non-depolarizing agents.

Hyperkalemic Vulnerability: When exposed to suxamethonium, widespread opening of extrajunctional receptors along the entire length of the muscle fiber causes massive, uncontrolled potassium efflux into the circulation.

2. Suxamethonium (Succinylcholine)

Suxamethonium is the only depolarizing neuromuscular blocking agent in clinical use. It consists chemically of two acetylcholine molecules joined back-to-back through their acetate methyl groups. (CH_3)_3N^+ - CH_2 - CH_2 - O - CO - CH_2 - CH_2 - CO - O - CH_2 - CH_2 - N^+(CH_3)_3

  • [ Suxamethonium Molecule ]
  • Mechanism of Action: The Depolarizing Blockade

Suxamethonium binds to both α 1 \alpha_1 α 1 ​ subunits of the n A C h R nAChR n A C h R and acts as a receptor agonist. It triggers channel opening and widespread endplate depolarization. Because junctional acetylcholinesterase cannot metabolize suxamethonium, the drug remains bound to the receptor, maintaining persistent postjunctional depolarization.

This continuous depolarization leads to voltage-dependent inactivation of perijunctional voltage-gated N a + Na^+ N a + channels (their inactivation h h h -gates close). Consequently, the perijunctional membrane cannot generate or propagate action potentials, producing complete flaccid skeletal muscle paralysis.

Phase I vs Phase II Block

Neuromuscular blockade produced by suxamethonium exhibits two distinct physiological phases:

Characteristic Phase I Block (Depolarizing) Phase II Block (Desensitization / Dual Block)

Mechanism Persistent postjunctional depolarization Receptor desensitization; membrane repolarizes but unexcitable

Onset Precursor Muscle fasciculations present No new fasciculations; occurs after high/prolonged exposure

Train-of-Four (TOF) No fade (TOF ratio = 1.0; all 4 twitches reduced equally) Marked fade (TOF ratio < 0.4; non-depolarizing pattern)

  • Tetanic Stimulation Sustained contraction (no fade) Marked tetanic fade
  • Post-Tetanic Count No post-tetanic potentiation Post-tetanic potentiation present

Anticholinesterase Effect Potentiated and prolonged (inhibition of butyrylcholinesterase) Unpredictable reversal (may antagonize or worsen block)

Triggering Doses Standard clinical bolus ( 1.0 − 1.5 mg/kg 1.0 - 1.5\text{ mg/kg} 1.0 − 1.5 mg/kg ) Cumulative dose > 3 − 5 mg/kg >3 - 5\text{ mg/kg} > 3 − 5 mg/kg or prolonged infusion

Metabolism and Butyrylcholinesterase Variants

Suxamethonium is metabolized in the plasma and liver by butyrylcholinesterase (pseudocholinesterase / plasma cholinesterase, coded by the B C H E BCHE BC H E gene on chromosome 3). Suxamethonium is cleaved into succinylmonocholine (possessing 1/20th to 1/50th neuromuscular blocking potency) and then slowly into succinic acid and choline. Less than 10% of the administered dose reaches the neuromuscular junction.

The Dibucaine Number Test

Dibucaine is an amide local anaesthetic that selectively inhibits normal, wild-type pseudocholinesterase by approximately 80% , but inhibits atypical pseudocholinesterase by only 20% . The Dibucaine Number is defined as the percentage of pseudocholinesterase enzymatic activity inhibited by dibucaine under standardized laboratory conditions. It evaluates the qualitative genetic function (phenotype) of the enzyme, NOT the quantitative circulating level. Dibucaine Number = [ 1 - (Enzyme Activity with Dibucaine / Enzyme Activity without Dibucaine) ] x 100

Genotype Allelic Pairing Dibucaine Number Frequency Clinical Duration of Suxamethonium

Homozygous Usual E 1 u E 1 u E_1^u E_1^u E 1 u ​ E 1 u ​ 70% - 85% (Normal ~80%) 96% of population Normal ( 5 − 10 minutes 5 - 10\text{ minutes} 5 − 10 minutes )

Heterozygous Atypical E 1 u E 1 a E_1^u E_1^a E 1 u ​ E 1 a ​ 50% - 60% ~1 in 25 to 50 Moderately prolonged ( 15 − 30 minutes 15 - 30\text{ minutes} 15 − 30 minutes )

Homozygous Atypical E 1 a E 1 a E_1^a E_1^a E 1 a ​ E 1 a ​ 16% - 25% (~20%) ~1 in 2,500 Profoundly prolonged (4 to 8 hours of apnea!)

Fluoride-Resistant E 1 f E 1 f E_1^f E_1^f E 1 f ​ E 1 f ​ Mildly reduced (about 60–70%); low fluoride number because the variant resists fluoride inhibition Rare Moderately prolonged ( 30 − 60 minutes 30 - 60\text{ minutes} 30 − 60 minutes )

Silent Gene E 1 s E 1 s E_1^s E_1^s E 1 s ​ E 1 s ​ Not measurable (no enzyme activity) ~1 in 100,000 Profoundly prolonged (4 to 8 hours of apnea!)

Clinical Trap: When managing prolonged apnea following suxamethonium in a homozygous atypical patient, do not administer neostigmine . Neostigmine inhibits any residual pseudocholinesterase activity, further prolonging the block. Management consists of continued mechanical ventilation, sedation, and patience until spontaneous recovery occurs.

Adverse Effects of Suxamethonium

Lethal Hyperkalemia: In healthy individuals, suxamethonium increases serum potassium by 0.5 mEq/L 0.5\text{ mEq/L} 0.5 mEq/L ( 0.5 mmol/L 0.5\text{ mmol/L} 0.5 mmol/L ) . In conditions with upregulated extrajunctional receptors, suxamethonium precipitates massive potassium efflux, raising serum potassium to > 8 − 10 mmol/L >8-10\text{ mmol/L} > 8 − 10 mmol/L and triggering immediate refractory ventricular fibrillation or asystolic arrest. Contraindicated in:

Severe thermal burns (vulnerable from 24-48 hours post-injury up to 1-2 years).

Massive denervation injury (spinal cord transection, ischemic stroke, peripheral nerve injury after 48-72 hours).

Prolonged intensive care immobility and severe abdominal sepsis.

Muscular dystrophies (e.g., Duchenne, Becker muscular dystrophy).

Severe motor neuropathies (e.g., Guillain-Barré syndrome, ALS).

Cardiac Dysrhythmias and Bradycardia: Stimulates muscarinic M 2 M_2 M 2 ​ receptors in the sinoatrial node, provoking severe sinus bradycardia, nodal escape rhythms, or sinus arrest. Most pronounced following a second dose administered within 5 minutes, or after a single dose in pediatric patients. Prevented by prior administration of intravenous atropine.

Elevated Compartment Pressures:

Intraocular Pressure (IOP): Increases by 5 to 10 mmHg for 5 to 10 minutes due to prolonged tonic contracture of extraocular rectus muscles and choroidal venous engorgement. Contraindicated in open-globe injuries.

Intragastric Pressure: Increases by 15 to 20 cmH 2 O \text{cmH}_2\text{O} cmH 2 ​ O due to abdominal wall fasciculations. However, lower esophageal sphincter (LES) barrier tone rises simultaneously, preserving the gastroesophageal pressure gradient in patients with intact sphincters.

Intracranial Pressure (ICP): Transient increase mediated by muscle spindle afferent stimulation; attenuated by a defasciculating dose of a non-depolarizing agent.

Postoperative Muscle Myalgia: Occurs in 20% to 50% of patients, particularly young ambulatory women. Caused by shearing micro-trauma during uncoordinated fasciculations. Attenuated by pretreatment with NSAIDs or a defasciculating dose (10% of E D 95 ED_{95} E D 95 ​ ) of a non-depolarizing blocker.

Malignant Hyperthermia (MH) Trigger: Potent trigger in patients with mutations in the skeletal ryanodine receptor ( R Y R 1 RYR1 R Y R 1 ) or voltage-gated calcium channel ( C A C N A 1 S CACNA1S C A CN A 1 S ) genes. Isolated masseter muscle spasm (MMS) following suxamethonium indicates high probability of MH susceptibility.

3. Non-Depolarizing Neuromuscular Blockers: General Principles

Non-depolarizing NMBDs act as competitive antagonists at the postjunctional n A C h R nAChR n A C h R . They bind to one or both α 1 \alpha_1 α 1 ​ subunits without inducing a conformational change, sterically obstructing endogenous acetylcholine from binding. Single twitch height depressed: >75% of receptors blocked

  • Train-of-Four count disappears (0 twitches): >90-95% of receptors blocked
  • Surgical relaxation achieved: 85-95% receptor block
  • Hallmarks of Non-Depolarizing Blockade

Fade on Train-of-Four (TOF): Progressive reduction in the height of successive twitches ( T 4 < T 3 < T 2 < T 1 T_4 < T_3 < T_2 < T_1 T 4 ​ < T 3 ​ < T 2 ​ < T 1 ​ ). Fade results from competitive antagonism of presynaptic nicotinic receptors , which normally facilitate the mobilization and vesicular release of acetylcholine during high-frequency repetitive nerve stimulation.

Tetanic Fade: Inability to sustain muscle contraction during 50 Hz or 100 Hz stimulation.

Post-Tetanic Facilitation: Enhanced twitch response following a tetanic train due to transient accumulation of presynaptic C a 2 + Ca^{2+} C a 2 + .

Reversibility: Fully antagonized by acetylcholinesterase inhibitors (neostigmine) or selective encapsulating agents (sugammadex).

4. Benzylisoquinolinium Compounds

Benzylisoquinoliniums are characterized by absence of steroidal rings and clearance mechanisms that are predominantly independent of renal or hepatic function. [ BENZYLISOQUINOLINIUMS ]

  • |
  • +--------------------------------+--------------------------------+
  • | |
  • [ ATRACURIUM ] [ CISATRACURIUM ]
  • Mixture of 10 stereoisomers - Single purified 1R-cis 1'R-cis isomer
  • Hofmann elimination (~1/3) - Hofmann elimination (77%)
  • Non-specific ester hydrolysis (~2/3) - Minimal laudanosine (5-10x less)
  • Generates laudanosine (epileptogenic) - 3 to 4 times more potent ($ED_{95} = 0.05$ mg/kg)
  • Histamine release at high doses - ZERO histamine release
  • Atracurium

Metabolism: Cleared through two distinct organ-independent pathways:

Hofmann Elimination (~33%): A purely chemical, non-enzymatic spontaneous molecular degradation that occurs at physiological body temperature ( 37 ∘ C 37^\circ\text{C} 3 7 ∘ C ) and pH (7.40). The rate of Hofmann elimination accelerates with alkalosis and hyperthermia, and decelerates with acidosis and hypothermia.

Non-specific Ester Hydrolysis (~67%): Enzymatic cleavage by ubiquitous plasma and tissue carboxylesterases (distinct from pseudocholinesterase).

Laudanosine Toxicity: Both degradation pathways generate laudanosine , a tertiary amine metabolite. Laudanosine readily crosses the blood-brain barrier and can induce central nervous system excitation, lowered seizure thresholds, and epileptogenic activity during prolonged high-dose infusions in the ICU, particularly in patients with concurrent renal failure (as laudanosine is eliminated by the kidneys).

Histamine Release: Rapid bolus administration stimulates mast cell degranulation, causing transient arterial hypotension, reflex tachycardia, cutaneous facial erythema, and bronchospasm.

Cisatracurium

Pharmacology: The purified 1 R -cis 1 ′ R -cis 1R\text{-cis } 1'R\text{-cis} 1 R -cis 1 ′ R -cis stereoisomer of atracurium. It is 3 to 4 times more potent than atracurium ( E D 95 ≈ 0.05 mg/kg ED_{95} \approx 0.05\text{ mg/kg} E D 95 ​ ≈ 0.05 mg/kg vs 0.2 mg/kg 0.2\text{ mg/kg} 0.2 mg/kg ).

Elimination: Cleared primarily by Hofmann elimination (77%) and renal excretion (16%). Non-specific ester hydrolysis plays a negligible role.

Clinical Superiority: Because of its higher potency, a substantially lower mass of drug is administered, generating 5- to 10-fold less laudanosine than atracurium. Crucially, cisatracurium causes zero histamine release even at 8 times its E D 95 ED_{95} E D 95 ​ , avoiding hemodynamic instability. It is the agent of choice in end-stage renal and hepatic failure.

Mivacurium

Pharmacology: Short-acting benzylisoquinolinium ( E D 95 ≈ 0.07 mg/kg ED_{95} \approx 0.07\text{ mg/kg} E D 95 ​ ≈ 0.07 mg/kg , duration 15-20 min).

Metabolism: Rapidly hydrolyzed by plasma butyrylcholinesterase (pseudocholinesterase) at 70% to 88% the rate of suxamethonium. Prolonged neuromuscular blockade occurs in patients with atypical pseudocholinesterase (homozygous atypical patients experience 4 to 8 hours of paralysis).

Adverse Effects: Rapid boluses provoke substantial histamine release and transient hypotension.

5. Aminosteroid Compounds

Aminosteroids feature a steroid nucleus with attached quaternary ammonium groups. They do not trigger histamine release and are amenable to selective encapsulation by sugammadex. [ AMINOSTEROIDS ]

  • |
  • +-------------------------------+-------------------------------+
  • | | |
  • [ ROCURONIUM ] [ VECURONIUM ] [ PANCURONIUM ]
  • Low potency ($ED_{95} = 0.3$) - Intermediate duration - Long duration (60-120 min)
  • Rapid onset (60-90 s at 1.2) - Hepatic deacetylation - Renal excretion (60-80%)
  • Hepatic uptake & biliary (70%) - Active 3-OH metabolite - Vagolytic tachycardia
  • Reversed by sugammadex - Accumulates in renal failure - Inhibits cardiac $M_2$
  • Rocuronium

Rapid Onset Principle: Rocuronium has a lower potency ( E D 95 ≈ 0.3 mg/kg ED_{95} \approx 0.3\text{ mg/kg} E D 95 ​ ≈ 0.3 mg/kg ) compared to vecuronium or pancuronium. Counterintuitively, lower potency produces faster onset of action : a lower potency requires administering a larger molar quantity of molecules to occupy the necessary receptor fraction (e.g., 1.2 mg/kg = 4 × E D 95 1.2\text{ mg/kg} = 4 \times ED_{95} 1.2 mg/kg = 4 × E D 95 ​ for RSI). This delivers a massive concentration gradient between the intravascular compartment and the neuromuscular biophase, driving rapid diffusion across the junctional cleft. At 1.2 mg/kg, excellent intubating conditions are achieved in 60 to 90 seconds , establishing rocuronium as the primary non-depolarizing alternative to suxamethonium for Rapid Sequence Induction.

Elimination: Cleared primarily unchanged via hepatic uptake and biliary excretion (~70%) , with renal excretion accounting for 10% to 30%. It has no active metabolites. Duration of action is prolonged in liver cirrhosis and advanced age.

Cardiovascular Profile: Hemodynamically inert at clinical doses; no histamine release.

Vecuronium

Pharmacology: Intermediate-acting aminosteroid with high potency ( E D 95 ≈ 0.05 mg/kg ED_{95} \approx 0.05\text{ mg/kg} E D 95 ​ ≈ 0.05 mg/kg ) and a slower onset of 2.5 to 3 minutes.

Metabolism and Active Metabolite: Undergoes hepatic deacetylation into three metabolites: 3-hydroxy, 17-hydroxy, and 3,17-dihydroxyvecuronium. The 3-hydroxyvecuronium metabolite possesses ~50% of the neuromuscular blocking potency of the parent drug and is eliminated exclusively by the kidneys. In renal impairment or following prolonged ICU infusions, 3-hydroxyvecuronium accumulates, precipitating prolonged paralysis.

Cardiovascular Stability: Devoid of autonomic side effects; does not cause histamine release.

Pancuronium

Pharmacology: Long-acting bisquaternary aminosteroid ( E D 95 ≈ 0.07 mg/kg ED_{95} \approx 0.07\text{ mg/kg} E D 95 ​ ≈ 0.07 mg/kg , duration 60-120 min).

Elimination: Predominantly cleared by renal excretion (60-80%).

Vagolytic Tachycardia: Pancuronium uniquely causes hypertension and tachycardia by competitively blocking cardiac muscarinic M 2 M_2 M 2 ​ receptors (vagolytic effect) and inhibiting sympathetic neuronal reuptake of norepinephrine.

6. Comprehensive Comparison Table of Neuromuscular Blockers

Agent Class E D 95 ED_{95} E D 95 ​ (mg/kg) Intubation Dose Onset Duration Primary Elimination / Metabolism Histamine Release

Suxamethonium Depolarizing 0.3 − 0.5 0.3 - 0.5 0.3 − 0.5 1.0 − 1.5 mg/kg 1.0 - 1.5\text{ mg/kg} 1.0 − 1.5 mg/kg 30 − 60 s 30 - 60\text{ s} 30 − 60 s 5 − 10 min 5 - 10\text{ min} 5 − 10 min Plasma butyrylcholinesterase Slight / Rare

Atracurium Benzylisoquinolinium 0.20 0.20 0.20 0.5 mg/kg 0.5\text{ mg/kg} 0.5 mg/kg 2 − 3 min 2 - 3\text{ min} 2 − 3 min 30 − 45 min 30 - 45\text{ min} 30 − 45 min Hofmann (1/3) & Ester hydrolysis (2/3) Yes (dose-dependent)

Cisatracurium Benzylisoquinolinium 0.05 0.05 0.05 0.15 − 0.2 mg/kg 0.15 - 0.2\text{ mg/kg} 0.15 − 0.2 mg/kg 2 − 3 min 2 - 3\text{ min} 2 − 3 min 40 − 60 min 40 - 60\text{ min} 40 − 60 min Hofmann elimination (77%) None

Mivacurium Benzylisoquinolinium 0.07 0.07 0.07 0.2 mg/kg 0.2\text{ mg/kg} 0.2 mg/kg 2 − 2.5 min 2 - 2.5\text{ min} 2 − 2.5 min 15 − 20 min 15 - 20\text{ min} 15 − 20 min Plasma butyrylcholinesterase Yes (rapid injection)

Rocuronium Aminosteroid 0.30 0.30 0.30 0.6 − 1.2 mg/kg 0.6 - 1.2\text{ mg/kg} 0.6 − 1.2 mg/kg 60 − 90 s 60 - 90\text{ s} 60 − 90 s (at 1.2) 35 − 75 min 35 - 75\text{ min} 35 − 75 min Hepatic uptake & biliary excretion (70%) None

Vecuronium Aminosteroid 0.05 0.05 0.05 0.1 mg/kg 0.1\text{ mg/kg} 0.1 mg/kg 2.5 − 3 min 2.5 - 3\text{ min} 2.5 − 3 min 30 − 45 min 30 - 45\text{ min} 30 − 45 min Hepatic metabolism (active 3-OH) & Renal None

Pancuronium Aminosteroid 0.07 0.07 0.07 0.1 mg/kg 0.1\text{ mg/kg} 0.1 mg/kg 3 − 4 min 3 - 4\text{ min} 3 − 4 min 60 − 120 min 60 - 120\text{ min} 60 − 120 min Renal excretion (60-80%); vagolytic None